Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - bisoprolol fumarate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - bisoprolol fumarate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - bisoprolol fumarate, quantity: 1.25 mg - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; calcium hydrogen phosphate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - bisoprolol fumarate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - bisoprolol fumarate, quantity: 3.75 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; calcium hydrogen phosphate; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - bisoprolol fumarate, quantity: 7.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; calcium hydrogen phosphate; crospovidone; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

United States - English - NLM (National Library of Medicine)

carilion materials management - bisoprolol fumarate (unii: ur59kn573l) (bisoprolol - unii:y41js2nl6u) - bisoprolol fumarate 5 mg - bisoprolol fumarate is indicated in the management of hypertension. it may be used alone or in combination with other antihypertensive agents. bisoprolol fumarate is contraindicated in patients with cardiogenic shock, overt cardiac failure, second or third degree av block, and marked sinus bradycardia.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), bisoprolol fumarate (unii: ur59kn573l) (bisoprolol - unii:y41js2nl6u) - hydrochlorothiazide 6.25 mg - bisoprolol fumarate and hydrochlorothiazide tablets are indicated in the management of hypertension. bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see warnings), second or third degree av block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), bisoprolol fumarate (unii: ur59kn573l) (bisoprolol - unii:y41js2nl6u) - hydrochlorothiazide 6.25 mg - bisoprolol fumarate and hydrochlorothiazide tablets are indicated in the management of hypertension. bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see warnings), second or third degree av block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs.

United States - English - NLM (National Library of Medicine)

directrx - bisoprolol fumarate (unii: ur59kn573l) (bisoprolol - unii:y41js2nl6u) - bisoprolol fumarate is indicated in the management of hypertension. it may be used alone or in combination with other antihypertensive agents. bisoprolol fumarate is contraindicated in patients with cardiogenic shock, overt cardiac failure, second or third degree av block, and marked sinus bradycardia.